scispace - formally typeset
F

Frank Erbguth

Researcher at Paracelsus Private Medical University of Salzburg

Publications -  140
Citations -  3088

Frank Erbguth is an academic researcher from Paracelsus Private Medical University of Salzburg. The author has contributed to research in topics: Stroke & Medicine. The author has an hindex of 24, co-authored 129 publications receiving 2707 citations. Previous affiliations of Frank Erbguth include University of Erlangen-Nuremberg.

Papers
More filters
Journal ArticleDOI

Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage.

TL;DR: Among patients with OAC-associated ICH, reversal of anticoagulation reversal and blood pressure (BP) with hematoma enlargement and resumption of OAC therapy was associated with lower risk of ischemic events, and these findings require replication and assessment in prospective studies.
Journal ArticleDOI

Neurological Symptoms in Type A Aortic Dissections

TL;DR: Aortic dissections might be missed in patients with neurological symptoms but without pain, and Neurological findings in elderly hypertensive patients with asymmetrical pulses or cardiac murmur suggest dissection.
Journal ArticleDOI

Neurologic manifestations of cerebral air embolism as a complication of central venous catheterization.

TL;DR: When caring for critically ill patients needing central venous catheterization, nursing staff and physicians should be aware of this potentially lethal complication.
Journal ArticleDOI

Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin.

Frank Erbguth
- 01 Mar 2004 - 
TL;DR: Today's botulinum toxin treatment was pioneered by Alan B. Scott and Edward J. Schantz, and some ancient dietary laws and taboos may reflect some knowledge about the life‐threatening consumption of poisoned food.
Journal ArticleDOI

Historical aspects of botulinum toxin: Justinus Kerner (1786–1862) and the “sausage poison”

TL;DR: Therapeutic chemodenervation with botulinum toxin type A has proved to be effective and safe in the treatment of conditions caused by focal contractions of skeletal muscles, such as strabismus, hemifacial spasm, focal dystonias, spasticity, and some autonomic disorders.